Energy and Commerce Committee
- Referred To
Introduced: Jan 28, 2025
Latest action date: Jan 28, 2025
Latest development
Referred to the House Committee on Energy and Commerce.
Status detail: The most advanced recorded stage is committee consideration.
Plain-language overview
Second Chance for Moms Act of 2025
This bill requires labeling of the drug mifepristone to include certain information about the hormone progesterone and establishes a related telephone hotline. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.)
Civixly topics
Civixly topics make federal and state legislation comparable. They are derived from the official CRS policy area and legislative subjects.
Official CRS policy area
Health
Committees and subcommittees that received, reviewed, marked up, or reported this legislation.
Proposed changes to this measure, with their latest official outcome or action from Congress.gov.
No amendments are listed for this measure.
Checked against Congress.gov Sep 15, 2026.
Newest action first. Action language comes from the official Congress.gov record.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Introduced in House
Recorded House and Senate votes connected to this bill. Your representatives appear first when available.
No connected roll-call votes are currently available for this bill.
0 comments
Loading comments...